Positive News SentimentPositive NewsNASDAQ:SLS SELLAS Life Sciences Group (SLS) News Today $1.68 +0.11 (+7.01%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$1.59▼$1.7050-Day Range$1.35▼$6.1552-Week Range$1.17▼$5.58Volume149,377 shsAverage Volume190,846 shsMarket Capitalization$47.63 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address SLS Media Mentions By Week SLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLS News Sentiment▼1.590.75▲Average Medical News Sentiment SLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLS Articles This Week▼21▲SLS Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meetingfinance.yahoo.com - May 25 at 6:47 PMSELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemiafinance.yahoo.com - May 16 at 9:19 AMSolaris Resources (CVE:SLS) Trading Down 2.7%americanbankingnews.com - May 14 at 6:54 AMSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Resultsfinanznachrichten.de - May 12 at 7:05 AMUnusual Call Option Trade in SELLAS Life Sciences Group (SLS) Worth $37.03Kmsn.com - May 11 at 7:28 PMSELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Resultsfinance.yahoo.com - May 11 at 6:19 PMSELLAS Life Sciences Group (SLS) Receives a Buy from Maxim Groupmarkets.businessinsider.com - May 5 at 2:40 PMSELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Studyfinance.yahoo.com - May 4 at 8:36 AMSELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meetingfinance.yahoo.com - April 26 at 6:35 PMSELLAS Life Sciences Group (SLS) Gets a Buy from Maxim Groupmarkets.businessinsider.com - April 21 at 1:06 PMSolaris Resources (CVE:SLS) Stock Rating Reaffirmed by National Bank Financialamericanbankingnews.com - April 21 at 6:14 AMSELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Plannedfinance.yahoo.com - April 18 at 8:47 AMCantor Fitzgerald Comments on SELLAS Life Sciences Group, Inc.'s FY2023 Earnings (NASDAQ:SLS)americanbankingnews.com - March 24 at 2:20 AMMaxim Group Remains a Buy on SELLAS Life Sciences Group (SLS)markets.businessinsider.com - March 18 at 10:00 AMSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Updatefinanznachrichten.de - March 17 at 7:35 AMSELLAS Life Sciences GAAP EPS of -$2.13 misses by $0.03, revenue of $1M in-linemsn.com - March 16 at 6:29 PMSELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Updatefinance.yahoo.com - March 16 at 6:29 PMSELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journalfinance.yahoo.com - March 7 at 9:39 AMWhy Sellas Life Sciences Shares Are Nosedivingmsn.com - February 24 at 4:46 PMSELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offeringfinance.yahoo.com - February 24 at 4:46 PMSellas Life Sciences raises $20 million from public offering of stock, warrantsfinance.yahoo.com - February 24 at 4:46 PMSellas Lift Sciences stock plunges to pace premarket decliners after stock, warrants offeringfinance.yahoo.com - February 24 at 8:01 AMHere's Why We're A Bit Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Situationfinance.yahoo.com - February 5 at 8:46 AMSELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Programfinance.yahoo.com - January 19 at 9:10 AMSELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairsfinance.yahoo.com - January 5 at 9:09 AMSELLAS Life Sciences Highlights Data From Early Study In Blood Cancer Patientsfinance.yahoo.com - December 13 at 5:59 PMSELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignanciesfinance.yahoo.com - December 13 at 8:45 AMLooking Into SELLAS Life Sciences Gr's Recent Short Interestmsn.com - December 8 at 4:11 PMSELLAS Life Sciences' Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Plannedtechnews.tmcnet.com - December 8 at 9:00 AMSELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Plannedfinance.yahoo.com - December 8 at 9:00 AMSELLAS Life Sciences’ CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institutefinance.yahoo.com - December 6 at 4:07 PMSELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Modelfinance.yahoo.com - December 1 at 6:41 PMSELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summitfinance.yahoo.com - November 30 at 8:41 AMSELLAS Life Sciences Group Third Quarter 2022 Earnings: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021)finance.yahoo.com - November 16 at 6:15 AMSELLAS Life Sciences Shares Tumble As Acute Myeloid Leukemia Trial Will Longer Than Anticipatedfinance.yahoo.com - November 15 at 10:08 AMSELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Resultsfinance.yahoo.com - November 14 at 12:59 PMSELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemiafinance.yahoo.com - November 14 at 7:59 AMSellas rises as GPS/Keytruda combo shows survival, disease control benefit in ovarian cancer trialseekingalpha.com - November 10 at 2:50 PMSELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancerfinance.yahoo.com - November 10 at 2:50 PMSELLAS Life Sciences' GPS Combo Therapy Shows Overall Survival Of 18 Months In Pretreated Ovarian Cancer Patientsfinance.yahoo.com - November 10 at 2:50 PMSELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meetingbenzinga.com - November 3 at 12:05 PMSELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meetingfinance.yahoo.com - November 3 at 10:02 AMSELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022finance.yahoo.com - November 2 at 4:00 PMThinking about buying stock in Taysha Gene Therapies, Nio, Traeger, Amprius Technologies, or Sellas Life Sciences?finance.yahoo.com - October 25 at 9:41 AMSELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022finance.yahoo.com - October 17 at 9:23 AMSELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-Sfinance.yahoo.com - October 11 at 8:36 AMSELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulationsfinance.yahoo.com - September 29 at 9:48 AMSELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meetingfinance.yahoo.com - September 22 at 8:44 AMSELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28thfinance.yahoo.com - September 14 at 9:14 AMSELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022finance.yahoo.com - September 8 at 8:08 AM Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ProMIS Neurosciences News NRx Pharmaceuticals News DiaMedica Therapeutics News Viracta Therapeutics News Medicenna Therapeutics News NextCure News LAVA Therapeutics News Sensei Biotherapeutics News TherapeuticsMD News Xenetic Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:SLS) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.